Pharma innovation summit in Boston

Mr Karun Rishi, president of the USA India Chamber of Commerce

Mr KV Subramaniam, chief executive officer, Reliance Life Sciences

Dr Martin Mackay, Co-Chair and Advisory Board member of the US-India BioPharma & Healthcare Summit

The USA-India Chamber of Commerce (USAIC), a bilateral Chamber of Commerce, will organize its annual US-India BioPharma & Healthcare Summit 2013 on June 21 at the Marriott Cambridge, Massachusetts, USA.

The Summit will focus on therapeutic areas of oncology and infectious diseases. Specific panels will deliberate the science, research trends, investments and market opportunities in these TAs along with discussions on BioPharma R&D strategy & trends; Industry-Academic Partnerships/Translational Research; Funding innovation & M&A trends.

The USA-India Chamber of Commerce BioPharma & Healthcare Summit 2013 will convene all the relevant parties including leading experts from industry, academia, investors and government to engage in active debate and idea generation on routes for successful collaboration between global companies and India’s burgeoning BioPharma industry and research sector. It will also focus on the role that academic institutions can play with specific attention paid to oncology, companion diagnostics and infectious diseases including HCV.

Prominent global R&D heads of leading pharma companies and academic leaders confirmed to participate include: Dr Elias Zerhouni, President Global R&D -Sanofi, Dr Jeffrey Flier, Dean, Harvard Medical School, Dr Martin Fitchet, Chief Operating Officer, Janssen R&D, Dr Bahija Jallal, Executive Vice President, MedImmune, Dr Edward Benz, President, Dana-Farber Cancer Institute, Dr Jeffrey Chodakewitz, SVP, Global Scientific Strategy, Merck & Co, Dr Ivan Gergel, Executive Vice President R&D- Endo Pharma, Dr Peter Mueller, Global Head of R&D- Vertex Pharmaceuticals and Dr JC Gutierrez-Ramos, SVP BioTherapeutics R&D, Pfizer. Prominent participants from India are: Dr Ramesh Deka, Director, All India Institute of Medical Sciences (AIIMS), Mr KV Subramaniam, Chief Executive Officer, Reliance Life Sciences, Mr Subir Basak, President GDDS, Jubilant Life Sciences, Mr Shambhu Kallolikar, Joint Secretary, Department of Pharmaceuticals, Dr Rashmi Barbhaiya,
Managing Director, Advinus and Dr Bindu Dey, Advisor, Department of Biotechnology. Dr MK Bhan and Dr GN Singh, Drug Controller General of India are also likely to participate.

“We are beginning to see R&D pipeline improving. Ideas introduced at our summit seven years ago are bearing fruits now. Pre competitive alliances and industry academic partnerships introduced at our summit earlier are part of a global pharma company strategy,” said Mr Karun Rishi, President of the USA India Chamber of Commerce.

Dr Martin Mackay, Co-Chair and Advisory Board member of the US-India BioPharma & Healthcare Summit: “I am delighted with the progress the USA-India Chamber of Commerce (BioPharma Summit) has been making for the past many years supported by our Knowledge Partner McKinsey & Company, who keep developing high quality analyses and thought provoking content to promote engagement amongst participating companies that leads to action. Today’s central question is: How can we deliver affordable innovation through global partnerships, and how can we remove barriers to collaboration—especially in Oncology and Infectious diseases.

Dr Mikael Dolsten, President Worldwide R&D, Pfizer and an Advisory Board member of USAIC: There has been tremendous growth in India’s innovative drug research industry over the past few years, and Pfizer is ensuring that we actively engage with potential R&D partners in India to accelerate our ability to deliver differentiated medicines to patients globally. This summit, organized by the USA-India Chamber of Commerce, has been valuable to us in building bridges with high quality researchers in India, and we look forward to these continued opportunities to identify potential partners.”

“India holds a vast and largely under-tapped pool of drug innovation resources and capabilities,” said Dr Ajay Dhankhar, a senior McKinsey partner and leader of McKinsey’s global R&D practice. “India will very likely become a Top-10 pharmaceutical market by 2020, and prices of drugs in India are arguably the lowest in the world. This combination of innovation, growing market, and affordable drugs makes India the perfect Petri-Dish to catalyze affordable innovation. The potential economic and social returns, if we can make this Petri-Dish deliver, are substantial and well within reach in the coming decade.”